UCLA Center for Clinical AIDS Research and Education
Welcome,         Profile    Billing    Logout  
 16 Trials 
15 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mitsuyasu, Ronald
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Active, not recruiting
3
91
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
12/23
04/25
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Active, not recruiting
2
23
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
12/25
06/26
NCT02390297: Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

Active, not recruiting
N/A
11
US
Blood tests
Calimmune, Inc.
HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
10/31
10/31
Haigentz, Missak
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
NCT03544723: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Recruiting
2
40
US
Ad-p53, anti-PD-1/anti-PD-L1, nivolumab, pembrolizumab, atezolizumab, durvalumab
MultiVir, Inc.
Solid Tumor, Lymphoma
06/22
12/22
BTCRC-LUN19-396, NCT04367311: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Recruiting
2
100
US
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Nasser Hanna, Genentech, Inc.
Lung Cancer, NSCLC
09/25
01/26
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/26
04/29
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed
1/2
24
US
ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro
Advaxis, Inc.
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
02/22
02/22
Rubinstein, Paul
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Active, not recruiting
2
23
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
12/25
06/26
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT05244473: A Safety Study of Brentuximab Vedotin in Participants With HIV

Withdrawn
1
48
US
brentuximab vedotin, ADCETRIS, Placebo, ART
Seagen Inc.
Human Immunodeficiency Virus
05/24
05/24
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Active, not recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Active, not recruiting
1
18
Europe, Canada, US
SGN-35T
Seagen Inc.
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30

Download Options